Call Now

Rhesus TNFRSF17 / BCMA Protein (Fc Tag)

TNFRSF17

Catalog Number P90103-C02H
Organism Species Rhesus
Host Human Cells
Synonyms TNFRSF17
Molecular Weight The recombinant rhesus TNFRSF17 comprises 294 amino acids and has a calculated molecular mass of 33 KDa.
predicted N Met
SDS-PAGE
Purity > 95 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the rhesus TNFRSF17 (XP_001106892.1) (Met1-Ala53) was expressed with the Fc region of human IgG1 at the C-terminus.
Bio-activity Measured by its binding ability in a functional ELISA. Immobilized human BAFF (P10056-HNCH) at 10 μg/ml (100 μl/well) can bind Rhesus TNFRSF17-Fc, The EC50 of Rhesus TNFRSF17-Fc is 0.03-0.07 μg/mL.
Research Area Cardiovascular |Angiogenesis |Cytokine & Receptor |Tumor Necrosis Factor & Receptor |TNF receptor
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.
Reference
  • Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94.
  • O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8.
  • Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.